Doctors can measure free and total carnitine levels and may also order an acylcarnitine profile to look for metabolic causes
The consensus statement recommends GLP-1/GIP therapy for: Adults with T1D who have overweight or obesity (BMI of 30 or higher, or 27 or higher with other health conditions) Adults with T1D who arent hitting their blood sugar goals with insulin alone, even at a healthy weight Teens and young adults with T1D who have overweight or obesity and arent reaching their targets on insulin or who are meeting targets but might still benefit If your BMI drops below 25, or was 25 or under when treatment started, your healthcare provider should check in regularly and may pause or stop the medication altogether
Caussy C, Reeder SB, Sirlin CB, Loomba R
FDA Approved: Yes (First approved November 8, 2023) Brand name: Zepbound Generic name: tirzepatide Dosage form: Injection Company: Eli Lilly and Company Treatment for: Weight Loss, Obstructive Sleep Apnea/Hypopnea Syndrome Add Drugs.com on Google Zepbound (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist used for weight reduction in adults with obesity or adults with overweight, and severe obstructive sleep apnea in adults with obesity
Fahrmann JF, Schmidt CM, Mao X, Irajizad E, Loftus M, Zhang J, Patel N, Vykoukal J, Dennison JB, Long JP et al